Skip to main content
Umang Swami
( out of 597 reviews )

Umang Swami, MD, MSCI, FASCO

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
1950 Circle of Hope
Salt Lake City , UT 84112

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106

Dr. Umang Swami is an Associate Professor in the Division of Oncology, Department of Internal Medicine, at Huntsman Cancer Institute, University of Utah. He serves as Section Leader for the Genitourinary Disease Group within the Division of Oncology and leads the Genitourinary Clinical Trials Research Group. He is a medical oncologist specializing in the care of patients with genitourinary cancers.

Dr. Swami earned his medical degree from Sawai Man Singh Medical College in India. He subsequently served as a Visiting Scientist at the Montefiore-Einstein Cancer Center in New York, where he contributed to Phase I studies evaluating novel drugs and treatment regimens for patients with refractory or advanced solid tumors. He completed his residency in Internal Medicine at St. Barnabas Hospital in New York, followed by a Hematology-Oncology fellowship and a Master of Science in Clinical Investigation from the University of Iowa College of Public Health. He has been recognized as a Fellow of the American Society of Clinical Oncology (FASCO).

Dr. Swami has authored more than 175 peer-reviewed publications and book chapters and has presented his work at leading international conferences, including ASCO, AACR, and ASBMT. He serves as a reviewer and editor for multiple journals and is an active member of several professional societies, including ASCO, AACR, ESMO, and SITC.

He is a member of the NCCN Guidelines Panel for Bladder and Penile Cancers and serves on several ASCO guideline panels, including those for systemic melanoma therapy, management of immune-related adverse events, germline genetic testing, cell-free DNA, and the Multi-Site Guideline Advisory Group. Within the University of Utah, Dr. Swami contributes to several institutional committees, including the Institutional Review Board, Tenure Advisory Committee, Radioactive Drug Research Committee, and the Human Use Subcommittee of the Radiation Safety Committee.

Dr. Swami is also deeply committed to mentoring medical students, residents, and fellows pursuing careers in oncology research.

Patient Rating

Patients consistently describe Dr. Swami as highly knowledgeable and up-to-date, with clear explanations of diagnoses, tests, and treatment options. Reviewers highlight his attentive, compassionate communication and willingness to listen, which helps them feel heard and confident in care decisions. Many also praise his responsive staff and personalized approach to treatment that supports patients’ peace of mind.

Generated via Patient Reviews

4.8 /5
( out of 597 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.


Sep 11, 2026
HUNTSMAN CANCER INSTITUTE

He is very good at listening to me and explaining everything very well. He has a great staff as well

Sep 06, 2026
HUNTSMAN CANCER INSTITUTE

So knowledgeable and professional. He made arrangements to see me and with his staff were well prepared to help me.

Jul 03, 2026
HUNTSMAN CANCER INSTITUTE

He is quite honestly the most intelligent Doctor I have ever met. So very glad he is my doctor.

May 06, 2026
SUGAR HOUSE HEALTH CENTER

Very capable professional

Apr 21, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Swami is good when we see him.

Apr 20, 2026
HUNTSMAN CANCER INSTITUTE

Just love him he is very knowledgeable and smart! So glad he is there to help me with my cancer

Apr 17, 2026
HUNTSMAN CANCER INSTITUTE

Dr.Swami has listened whe we've asked multiple questions whether in person or messsaged on the MY Charte app, and he and his staff have responded promptly to each inquiry which is greatly appreciated. To date I am very comfortable with Dr. Swami and belive he will guide me to making the best choices and decisions for treatment as we move forward.

Apr 13, 2026
SUGAR HOUSE HEALTH CENTER

Interesting approach. Diagrams and pictures (not professionally drawn) but identifiable. Great presentation of my cancer and the type of treatment necessary. He explained all my choices and helped me to the decision that I thought was the right one for me. It was a lot of information to absorb and Dr. Swami took the time to explain everything, sometimes 2 or 3 times as I did not get it all on the first go around. Considering why I was there; I was happy for the doctor that I had handling my treatment.

Mar 24, 2026
HUNTSMAN CANCER INSTITUTE

After my initial consultation with Dr, Swami I felt confident in the course of treatment.

Mar 22, 2026
HUNTSMAN CANCER INSTITUTE

Excellent professional

Mar 22, 2026
HUNTSMAN CANCER INSTITUTE

Strong expertise, very good communication skills

Mar 16, 2026
HUNTSMAN CANCER INSTITUTE

Great Dr. and has a very good staff for support.

Feb 23, 2026
HUNTSMAN CANCER INSTITUTE

A good doctor.

Feb 22, 2026
HUNTSMAN CANCER INSTITUTE

Dr Swani. Is an excellent doctor who understands and supports his clients needs.

Feb 20, 2026
HUNTSMAN CANCER INSTITUTE

Sooooo Good! [TRANSLATED]

Feb 16, 2026
SUGAR HOUSE HEALTH CENTER

Incredibly knowledgeable, very personable extremely kind

Feb 14, 2026
HUNTSMAN CANCER INSTITUTE

Very efficient [TRANSLATED]

Feb 08, 2026
HUNTSMAN CANCER INSTITUTE

We didn't know how to give the rating on the previous page as we never had Dr. Swami appear on the call. Only his PA appeared after 45 minutes of waiting.

Feb 06, 2026
SUGAR HOUSE HEALTH CENTER

Dr. Swami cares and makes sure my concerns are answered.

Feb 04, 2026
HUNTSMAN CANCER INSTITUTE

Knowledgeable, caring, willing to listen

Jan 16, 2026
HUNTSMAN CANCER INSTITUTE

Very smart and up to date on treatment options. Concerned that all medical issues are addressed (including cardiology and hematology) before best treatment is recommended.

Jan 16, 2026
HUNTSMAN CANCER INSTITUTE

He cares about his patients and answers questions patiently and with concern,

Jan 10, 2026
HUNTSMAN CANCER INSTITUTE

He is a great doctor, the treatment he picked for me 6 months ago, is working very good. He listened my concerns and understood my fears . He is smart and flexible trying to find a point of balance vetween my fears and my treatment and I think that is a beautiful skill in a doctor, for me, means he care about not just my body health but also my peace of mind. We are body, soul and mind, and in the treatment of cancer for me it was very important he listened and understood those 3 sides of myself.....I am very grateful to him and wish him a long and beautiful life helping people like me as he is doing.....

Dec 18, 2025
SUGAR HOUSE HEALTH CENTER

Very professional and nice. He explained everything regarding my condition and answered my questions so I could understand.

Dec 16, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Swami is very good and has an excellent staff.

Dec 14, 2025
HUNTSMAN CANCER INSTITUTE

Very competent and caring

Nov 28, 2025
SUGAR HOUSE HEALTH CENTER

Dr. Swami was very pleasant to work with, he explained things so that I understood. He and his staff were on time and responsive to my needs.

Nov 17, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Swamy was good however his accent was sometimes difficult to understand.

Nov 15, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Swami , is a very intelligent caring doctor , I highly recommend Dr. Swami .

Nov 13, 2025
SUGAR HOUSE HEALTH CENTER

Top notch.

Nov 07, 2025
HUNTSMAN CANCER INSTITUTE

Listened to my concerns and explained what I would be going throughout my treatment.

Oct 10, 2025
HUNTSMAN CANCER INSTITUTE

He and his team are oustanding

Oct 08, 2025
HUNTSMAN CANCER INSTITUTE

Not on time always 20 to 45 minutes late

Oct 01, 2025
SUGAR HOUSE HEALTH CENTER

Excellent approach to treatment process and followup. Versatile. Not afraid to try to use an alternate approach if the current approach is not getting the response desired.

Sep 16, 2025
HUNTSMAN CANCER INSTITUTE

Dr. was thorough with all the information he provided, and we understood everything. He took the time needed to explain in detail what needed to be said. I believe he truly cares about you as an individual.

Aug 19, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Swami cares about his patients.

Aug 15, 2025
HUNTSMAN CANCER INSTITUTE

Very knowledgeable

Aug 11, 2025
HUNTSMAN CANCER INSTITUTE

I'm not Cancer doctor great he seems to be well. Knowledge infield which is reassuring. Pays close attention to things and change the medication very quickly that was not working having his team or fantastic. Thank you for him.

Aug 04, 2025
HUNTSMAN CANCER INSTITUTE

Dr Swami is kind and explains labs and other tests in detail. Has researched future treatments going forward with my care. I feel comfortable with decisions we make together.

Jul 19, 2025
HUNTSMAN CANCER INSTITUTE

My situation is totally in his hands, so I trust him completely.

Jul 10, 2025
HUNTSMAN CANCER INSTITUTE

Poor time management for the appointment. 45 minutes late on a virtual call

Jun 13, 2025
HUNTSMAN CANCER INSTITUTE

excellent practicianer

Jun 06, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Swami is caring and listens when I have concerns.

May 29, 2025
SUGAR HOUSE HEALTH CENTER

Ideal MD for a person with a cancer diagnosis

May 10, 2025
HUNTSMAN CANCER INSTITUTE

He has been so accommodating to my needs and is very professional in his dealings

May 04, 2025
HUNTSMAN CANCER INSTITUTE

The doctor was unavailabe due to a medical emergency.

May 02, 2025
SUGAR HOUSE HEALTH CENTER

Dr Swami understood my concerns as a retired physician and presented the approach to my care which made excellent sense to me.

Apr 27, 2025
HUNTSMAN CANCER INSTITUTE

Very informative and kind man.

Apr 23, 2025
SUGAR HOUSE HEALTH CENTER

Does a very efficient job and modifies his approach based upon the response of the patient. Very precise in discussing test findings which is shared with patient.

Apr 05, 2025
HUNTSMAN CANCER INSTITUTE

Dr. swami is very kind and willing to listen and answer all our questions


Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Oncology

Selected Publications

Journal Article

  1. Sayegh N, Jo Y, Swami U, Nandakumar V, Gebrael G, Ozay ZI, Li H, Goel K, Maughan BL, Plets M, Hussain MHA, Dorff TB, Lara PN Jr, Goldkorn A, Lerner SP, Agarwal N (2026). Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG-1216 Phase 3 Trial. Prostate.
  2. Nandakumar V, Jo Y, Ostrowski M, Gebrael G, Ozay ZI, Lin E, Goel K, Revillo R, Upadhyay L, Agarwal T, Sayegh N, Mathew Thomas V, Li H, Agarwal N, Swami U (2026). Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer. JAMA Netw Open, 9(10), e2639276.
  3. Gebrael G, Jo Y, Nandakumar V, Ozay ZI, Mercinelli C, Hooper G, Ostrowski M, Sayegh N, Lin E, Goel K, Li H, Thomas VM, Gupta S, Guha A, Riaz IB, Agarwal N, Swami U (2026). Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open, 9(10), e2639458.
  4. Crockett E, Schmidt B, Rodriguez O, Taylor A, Braun E, Leonhart S, Swami U, Boucher KM, Chapman L, Davis H, Linton J, Mangelson E, Johnson S, Tward J, Odei B, Yap J, Gupta S, Kohli M, Agarwal N, Dechet C, ONeil B, Maughan BL, Sanchez A (2026). Salvage Metastasis-Directed Therapy Without Androgen Deprivation for Positron Emission Tomography-Defined Oligorecurrent Prostate Cancer: Results of the SOAR Phase II Trial. JU Open Plus, 4(9), e00101.
  5. McKay RR, Ballman KV, Atherton PJ, Ajmera A, Al Baghdadi T, Baumann BC, Beltran H, Berg S, Chen RC, Choudhury AD, Cole S, Jacene HA, Lang JM, Kilari D, Kwok Y, McGregor B, Morris MJ, Parikh M, Swami U, Tan A, Yang YA, Zhang T, Galsky M, Rosenberg J, George D, Choueiri TK (2026). Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol, 44(24), 2341-2352.
  6. Feng BJ, Fatema K, Nix DA, Atkinson A, Caparas C, Stubben CJ, Lum DH, Parnell TJ, Carroll C, Grass GD, Graham L, Singer EA, Nepple KG, Manojlovic Z, Kauffman E, King JM, Ghodoussipour S, Hensley P, Viscuse PV, Ayanambakkam A, Churchman ML, Swami U, Agarwal N, Cairns BR, Gupta S (2026). SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma. bioRxiv.
  7. Nandakumar V, Jo Y, Gebrael G, Ozay ZI, Upadhyay L, Goel K, Sayegh N, Srivastava A, Ostrowski M, Hardy T, Lin E, Thomas VM, Maughan BL, Li H, Agarwal N, Swami U (2026). Real-world Effectiveness of Single-Agent Tivozanib in Patients with Metastatic Clear Cell Renal Cell Carcinoma. J Kidney Cancer VHL, 13(3), 27-33.
  8. Swami U, Agarwal N, Thompson A, Assayag J, Kirker M, Shaman S, Kim CH, Hanson S, Barata P (2026). Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States. Clin Genitourin Cancer, 24(5), 102574.
  9. Sweeney CJ, Krishna V, Krishna V, Neema A, Tarsode A, Subhash VV, Horvath LG, Kench JG, Stockler MR, Yip S, Thomas H, Swami U, Zhang H, Sonawane S, Abuzeid WM, Nimgaonkar V, Tiu E, Watson D, Kiedrowski L, Royce TJ, Yang DD, Tran PT, Ryan CJ, Nguyen PL, Morgans AK, Joshi A, Agarwal N, Davis ID (2026). Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials. JCO Precis Oncol, 10(7), e2600321.
  10. Lockwood CM, Messersmith HJ, Kim AS, Rajagopal PS, Swami U, Xian R, Aisner D, Arcila ME, Kurttila F, Lovly CM, Merker JD, Nair KG, Ntekim AI, Sheen MA, Tsimberidou AM, Turner NC, Gray SW (2026). Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline. JCO Oncol Pract, OP2600311.
  11. Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U (2026). Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open, 9(6), e2620084.
  12. Hooper G, Jo Y, Nandakumar V, Gebrael G, Ozay ZI, Ostrowski M, Hardy T, Lin E, Campbell P, Murdock EG, Upadhyay L, Goel K, Thomas VM, Li H, Sokolova AO, Swami U, Agarwal N (2026). Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open, 9(6), e2620750.
  13. Swami U, Agarwal N, Thompson A, Assayag J, Kirker M, Shaman S, Kim CH, Hanson S, Barata P (2026). Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States. Clin Genitourin Cancer, 24(5), 102574.
  14. Flaig TW, Spiess PE, Abern M, An Y, Bangs R, Begovic J, Brown J, Buyyounouski MK, Chan K, Chang P, Chin AI, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kundu S, Lele SM, Luckenbaugh A, Maldonado J, Mei L, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Seyedin S, Siefker-Radtke AO, Stewart T, Sundi D, Swami U, Tollefson M, Wright JL, Cassara CJ, Sliker B (2026). Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw, 24(5), 186-203.
  15. Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Flchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T (2026). How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. Future Oncol, 22(9), 1015-1029.
  16. Hage Chehade C, Ozay ZI, Jo Y, Gebrael G, Sayegh N, Ostrowski M, Srivastava A, Garg D, Hardy T, Murdock EG, Narang A, Mathew Thomas V, Li H, Maughan BL, Roy S, Agarwal N, Swami U (2026). Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States. JAMA Netw Open, 9(4), e265585.
  17. Gebrael G, Jo Y, Ozay ZI, Nandakumar V, Cigliola A, Tateo V, Lin E, Ostrowski M, Sayegh N, Murdock E, Mathew Thomas V, Gupta S, Agarwal N, Swami U (2026). Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. Bladder Cancer, 12(1), 23523735261437911.
  18. Expert Panel on Systemic Oncology, Mejias C, Morgan RL, Arora SS, Carter BW, Chundury A, Corey AS, Kim L, Morin CE, Swami U, Terando A, Vorenkamp AE, Wolfman DJ, Wong TZ (2026). ACR Appropriateness Criteria® Staging and Follow-Up of Melanoma. J Am Coll Radiol.
  19. Sayegh N, Graf RP, Swami U, Ozay ZI, Hage Chehade C, Elvin JA, Lin D, Quintanilha JCF, Li G, Bryce AH, McKay RR, Ross JS, Zhang T, Agarwal N (2025). Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res, 32(4), 801-812.
  20. Swami U, Shao Q, Alfred T, Touya M, Cao F, Kamdar P, Ivanova J, Celli J, Nimke D (2026). Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer. Prostate.
  21. Gebrael G, Agarwal N, Morgans AK, Vince R Jr, Swami U, Jia AY, Zaorsky N, Chehade CH, Ozay ZI, Malone S, Morgan SC, Wallis CJD, Kishan AU, Barata PC, Chowdhury S, Garcia JA, Sheng I, Brown JR, Small EJ, Sun Y, Shore ND, Saad F, Spratt DE, Roy S (2025). Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer, 132(1), e70236.
  22. Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt DE (2025). Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer. Nat Commun, 17(1), 667.
  23. Nahle T, Makram OM, Shah VR, Hyma Kunhiraman H, Afzal MU, Riaz IB, Agarwal N, Swami U, Rachoin JS, Weintraub NL, Guha A (2025). Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancer. JNCI Cancer Spectr, 9(6).
  24. Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami U (2025). Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations. JAMA Netw Open, 8(10), e2534968.

Review

  1. Ozay ZI, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Swami U, Agarwal N (2026). Antibody-drug conjugates in prostate cancer: current landscape and future directions. [Review]. Ther Adv Med Oncol, 18, 17588359261424672.

Editorial

  1. Nandakumar V, Agarwal T, Gupta S, Swami U (2026). Clinical Trial Access in Renal Cell Carcinoma: When Innovation Does Not Reach the Communities That Need It. JCO Oncol Pract, OP2601037.